New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment
Researchers from B·ARGO and the Urological Tumour Unit at IGTP and ICO have led a study proposing a new therapeutic strategy based on a combination of kinase inhibitors for metastatic prostate cancer patients who have progressed on standard treatment. The study has been published in the journal Frontiers in Pharmacology.